Alnylam Shares Edge Up 0.11% on $480M Volume (Rank 222nd) as RNAi Pipeline Drives 70%+ Total Return

On September 2, 2025, Alnylam Pharmaceuticals (ALNY) rose 0.11% with a trading volume of $0.48 billion, ranking 222nd in market activity. Recent developments highlight progress in its cardiovascular pipeline, including advancing zilebesiran into global Phase III trials for hypertension, a partnership with Roche, and positive data from the HELIOS-B Phase III study on vutrisiran for ATTR-CM. Analysts noted renewed investor interest, with ClearBridge All Cap Growth Strategy citing Alnylam’s RNAi leadership and Amvuttra’s long-term cardiovascular benefits as key differentiators. Institutional activity included purchases by Point72 Europe and Panagora Asset Management, reflecting strategic positioning in growth-oriented biotech assets.

Despite mixed clinical outcomes, Alnylam’s focus on RNAi therapeutics and rare disease treatments remains a core driver. The company’s Amvuttra franchise, targeting transthyretin amyloid cardiomyopathy, demonstrated sustained mortality reduction in extended HELIOS-B data. Meanwhile, collaborations with Genentech and Roche underscore its role in addressing unmet needs in hypertension and neurodegenerative diseases. While competitive pressures from emerging startups and regulatory risks persist, the stock’s 1-year total return of 70.16% outperformed the S&P 500’s 13.58%, supported by its platform’s scalability and pipeline diversification.

Backtest results for ALNY from 2022 to 2025 show a 117.57% total return over three years, compared to the S&P 500’s 63.48%. The stock’s 1-year performance of 70.16% and year-to-date gain of 89.96% highlight its resilience in biotech sector rotations. These figures align with its pipeline advancements and institutional investment trends, though valuation metrics suggest caution amid sector-wide volatility.